Travere Therapeutics, Inc.
TVTX · Nasdaq · United States
Share price · TVTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TVTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026-4.1%
- Day beforeDirector or principal officer change
- 5 Aug 2026+12.0%
- 14 Apr 2026+37.2%
- Ligand Pharmaceuticals: Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGSLGND +8.9%
- 13 Feb 2026-9.1%
Nothing announced by TVTX that day or the session before.
- 13 Jan 2026-14.6%
Nothing announced by TVTX that day or the session before.
- 6 Jan 2026-6.1%
Nothing announced by TVTX that day or the session before.
- 24 Dec 2025+13.9%
Nothing announced by TVTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TVTX's own-move activity since 10 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
sparsentan (Filspari)events and moves
| 4 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 36% |
| Other company news (earnings, financing, releases naming no asset) | — | 6% |
| Sessions with no dated event | — | 58% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
sparsentan(Filspari) | Approved | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule | Focal Segmental GlomerulosclerosisIgA Nephropathy |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
March 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (17)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $225M | $70M | $124M+ $180M short-term inv. | $52M$98M operating cash flow | report ↗ |
View 16 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $170M | $60M | $118M+ $176M short-term inv. | $35M$58M operating cash flow | report ↗ |
| 2026-Q1 | $127M | $57M | $78M+ $131M short-term inv. | $37M-$40M operating cash flow | report ↗ |
| 2025-Q3 | $165M | $52M | $111M+ $139M short-term inv. | —$14M operating cash flow | report ↗ |
| 2025-Q2 | $114M | $49M | $75M | $13M$5.0M operating cash flow | report ↗ |
| 2025-Q1 | $82M | $47M | $62M | $41M-$42M operating cash flow | report ↗ |
| 2024-Q3 | $63M | $52M | $36M+ $219M short-term inv. | $55M-$43M operating cash flow | report ↗ |
| 2024-Q2 | $54M | $54M | $32M+ $222M short-term inv. | $70M-$40M operating cash flow | report ↗ |
| 2024-Q1 | $41M | $49M | $43M+ $241M short-term inv. | $136M-$119M operating cash flow | report ↗ |
| 2023-Q4 | $45M | — | $58M+ $249M short-term inv. | $90M-$70M operating cash flow | report ↗ |
| 2023-Q3 | $37M | $61M | $144M+ $213M short-term inv. | —-$59M operating cash flow | report ↗ |
| 2023-Q2 | $60M | $69M | $71M+ $231M short-term inv. | $86M-$69M operating cash flow | report ↗ |
| 2023-Q1 | $57M | $60M | $161M+ $279M short-term inv. | $86M-$81M operating cash flow | report ↗ |
| 2022-Q4 | $29M | — | $62M+ $286M short-term inv. | $66M-$55M operating cash flow | report ↗ |
| 2022-Q3 | $54M | $59M | $151M+ $297M short-term inv. | $70M-$40M operating cash flow | report ↗ |
| 2022-Q2 | $54M | $60M | $180M+ $329M short-term inv. | $67M-$37M operating cash flow | report ↗ |
| 2022-Q1 | $48M | $57M | $257M+ $273M short-term inv. | $76M-$55M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $491M | $206M | $93M+ $145M short-term inv. | $6.4M$38M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $233M | $218M | $59M | $80M-$237M operating cash flow | report ↗ |
| 2023-FY | $145M | $245M | $58M+ $249M short-term inv. | $28M-$280M operating cash flow | report ↗ |
| 2022-FY | $212M | $236M | $62M+ $286M short-term inv. | $70M-$186M operating cash flow | report ↗ |
| 2021-FY | $227M | $210M | $166M+ $262M short-term inv. | $45M-$15M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 118 sales ($110.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Option exercise | 43,735 | $26.88 | $1.2M | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Option exercise | 200,000 | $8.93 | $1.8M | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 128,065 | $52.97 | $6.8M | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 37,270 | $54.20 | $2.0M | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Open-market sale | 78,400 | $55.02 | $4.3M | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Option exercise (derivative) | 43,735 | — | — | Form 4 |
| 2026-10-15 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Option exercise (derivative) | 200,000 | — | — | Form 4 |
| 2026-09-17 | Dube Eric M · director, CHIEF EXECUTIVE OFFICER | Option exercise | 108,493 | $23.34 | $2.5M | Form 4 |